CNS Pharmaceuticals Inc. has reported its financial results for the first quarter of 2025, ending March 31. The company recorded a net loss of approximately $4.3 million, an increase from the net loss of about $3.5 million during the same period in 2024. This change is largely attributable to the costs associated with data clean-up, preparation, and analysis for the topline primary data release on the Berubicin trial. Research and development expenses rose to $3.2 million from approximately $2.5 million in the previous year, primarily due to these same costs. Meanwhile, general and administrative expenses slightly decreased to approximately $1.09 million compared to $1.11 million for the comparable period in 2024. As of March 31, 2025, CNS Pharmaceuticals had cash reserves of approximately $13.1 million. Following the end of the quarter, the company completed a public offering that yielded gross proceeds of approximately $5 million. The company expects these funds to support operations into the second half of 2026. CNS Pharmaceuticals continues to advance its lead program, TPI 287, aiming to begin a Phase 2 study for glioblastoma multiforme by the end of 2025.